|
|
|
|
| LEADER |
03675nmm a2200373 u 4500 |
| 001 |
EB000364656 |
| 003 |
EBX01000000000000000217708 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
130626 ||| eng |
| 020 |
|
|
|a 9781461446699
|
| 100 |
1 |
|
|a Abood, Mary E.
|e [editor]
|
| 245 |
0 |
0 |
|a endoCANNABINOIDS
|h Elektronische Ressource
|b Actions at Non-CB1/CB2 Cannabinoid Receptors
|c edited by Mary E. Abood, Roger G Sorensen, Nephi Stella
|
| 250 |
|
|
|a 1st ed. 2013
|
| 260 |
|
|
|a New York, NY
|b Springer New York
|c 2013, 2013
|
| 300 |
|
|
|a XII, 288 p
|b online resource
|
| 505 |
0 |
|
|a Overview of Non-Cannabinoid Receptors.Overview of Non-Classical Cannabinoid Receptors.Overview of Non-Cannabinoid Receptors: Chemistry and Modeling -- G-Protein Coupled Receptors.GPR55 in the CNS.The Role of GPR55 in Bone Biology.The Role of GPR55 in Cancer.GPR18 and NAGly signaling: New members of the endocannabinoid family or distant cousins?.Cannabinoid Signaling Through Non CB1/Non CB2 GPCR Targets in Microglia -- Ion Channels.Temperature-Sensitive Transient Receptor Potential Channels as Ionotropic Cannabinoid Receptors.Nonpsychoactive Cannabinoid Action on 5-HT3 and Glycine Receptors -- Transcription Factors.Peroxisome proliferator-activated receptors and inflammation.Peroxisome proliferator-activated nuclear receptors (PPAR) and drug addiction -- Conclusions/Therapeutic Potential.Conclusions: Therapeutic Potential of Novel Cannabinoid Receptors
|
| 653 |
|
|
|a Neuroscience
|
| 653 |
|
|
|a Proteins
|
| 653 |
|
|
|a Neurosciences
|
| 653 |
|
|
|a Human Physiology
|
| 653 |
|
|
|a Human physiology
|
| 653 |
|
|
|a Physiology
|
| 653 |
|
|
|a Animal Physiology
|
| 653 |
|
|
|a Pharmacology
|
| 700 |
1 |
|
|a Sorensen, Roger G.
|e [editor]
|
| 700 |
1 |
|
|a Stella, Nephi
|e [editor]
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b Springer
|a Springer eBooks 2005-
|
| 490 |
0 |
|
|a The Receptors
|
| 028 |
5 |
0 |
|a 10.1007/978-1-4614-4669-9
|
| 856 |
4 |
0 |
|u https://doi.org/10.1007/978-1-4614-4669-9?nosfx=y
|x Verlag
|3 Volltext
|
| 082 |
0 |
|
|a 612.8
|
| 520 |
|
|
|a The cloning of two G protein-coupled cannabinoid receptors, termed CB1 and CB2, in the early 1990s has stimulated and facilitated research conducted on the physiological function of cannabinoid actions in the brain and throughout the body. In the twenty years since the identification of these two receptors, endogenous ligands (endocannabinoids) for these receptors have been identified, their biosynthetic and metabolic pathways have been discerned, and their functional and regulatory action for signalling through CB1 and CB2 receptors have been described. More recently, it has become has become evident that cannabinoids exert actions at non-CB1, non-CB2 receptors. Much less is understood about these actions. Many of these novel “targets” are in the process of being characterized functionally and physiologically, and the therapeutic value of targeting these non-CB1, non-CB2 receptors is being evaluated. The purpose of this volume is to present the current knowledge on the atypical actions of cannabinoids on these new targets. This book is intended as a scientific resource for cannabinoid researchers carrying out animal and human experiments, and for those who are interested in learning about future directions in cannabinoid research. Additionally, this book may be of value to investigators currently working outside the field of cannabinoid research who have an interest in learning about these compounds and their atypical cannabinoid signalling. This book provides insight into the potential medical application of cannabinoids and their therapeutic development for the treatment of human disease
|